Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogeni… Read more
Theravance Biopharma Inc (TBPH) - Net Assets
Latest net assets as of September 2025: $232.68 Million USD
Based on the latest financial reports, Theravance Biopharma Inc (TBPH) has net assets worth $232.68 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($415.46 Million) and total liabilities ($182.78 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $232.68 Million |
| % of Total Assets | 56.01% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -27.78% |
| Growth Volatility | 57.69 |
Theravance Biopharma Inc - Net Assets Trend (2011–2024)
This chart illustrates how Theravance Biopharma Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Theravance Biopharma Inc (2011–2024)
The table below shows the annual net assets of Theravance Biopharma Inc from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $175.54 Million | -17.58% |
| 2023-12-31 | $213.00 Million | -51.79% |
| 2022-12-31 | $441.80 Million | +230.49% |
| 2021-12-31 | $-338.57 Million | -11.46% |
| 2020-12-31 | $-303.75 Million | -35.70% |
| 2019-12-31 | $-223.84 Million | -333.89% |
| 2018-12-31 | $-51.59 Million | -144.79% |
| 2017-12-31 | $115.18 Million | -67.11% |
| 2016-12-31 | $350.23 Million | +44.09% |
| 2015-12-31 | $243.06 Million | -16.12% |
| 2014-12-31 | $289.79 Million | +1801.13% |
| 2013-12-31 | $-17.04 Million | -896.20% |
| 2012-12-31 | $-1.71 Million | +98.78% |
| 2011-12-31 | $-140.72 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Theravance Biopharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 82479800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $7.00K | 0.00% |
| Other Components | $1.14 Billion | 650.01% |
| Total Equity | $175.54 Million | 100.00% |
Theravance Biopharma Inc Competitors by Market Cap
The table below lists competitors of Theravance Biopharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guangdong Lyric Robot Automation Co Ltd
SHG:688499
|
$315.37 Million |
|
Cembre S.p.A.
F:J0L
|
$315.46 Million |
|
Shoei Co Ltd
PINK:SHOFF
|
$315.56 Million |
|
STEF S.A
LSE:0NY3
|
$315.59 Million |
|
China Aviation Oil (Singapore) Corporation Ltd
F:VZ8
|
$315.20 Million |
|
POTBELLY - Frankfurt Stock Exchang
F:PTB
|
$315.15 Million |
|
Fulgent Genetics Inc
NASDAQ:FLGT
|
$315.12 Million |
|
YIFILASER ORD A (SHH) EQSW Exp:
SHG:688646
|
$315.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Theravance Biopharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 212,995,000 to 175,545,000, a change of -37,450,000 (-17.6%).
- Net loss of 56,418,000 reduced equity.
- Share repurchases of 3,104,000 reduced equity.
- New share issuances of 99,000 increased equity.
- Other comprehensive income increased equity by 72,000.
- Other factors increased equity by 21,901,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-56.42 Million | -32.14% |
| Share Repurchases | $3.10 Million | -1.77% |
| Share Issuances | $99.00K | +0.06% |
| Other Comprehensive Income | $72.00K | +0.04% |
| Other Changes | $21.90 Million | +12.48% |
| Total Change | $- | -17.58% |
Book Value vs Market Value Analysis
This analysis compares Theravance Biopharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.87x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-4.41 | $13.92 | x |
| 2012-12-31 | $-0.22 | $13.92 | x |
| 2013-12-31 | $-0.53 | $13.92 | x |
| 2014-12-31 | $9.13 | $13.92 | x |
| 2015-12-31 | $7.12 | $13.92 | x |
| 2016-12-31 | $7.83 | $13.92 | x |
| 2017-12-31 | $2.20 | $13.92 | x |
| 2018-12-31 | $-0.96 | $13.92 | x |
| 2019-12-31 | $-4.03 | $13.92 | x |
| 2020-12-31 | $-4.87 | $13.92 | x |
| 2021-12-31 | $-4.87 | $13.92 | x |
| 2022-12-31 | $6.00 | $13.92 | x |
| 2023-12-31 | $3.85 | $13.92 | x |
| 2024-12-31 | $3.59 | $13.92 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Theravance Biopharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -32.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -87.63%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 2.02x
- Recent ROE (-32.14%) is below the historical average (-22.83%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | -736.06% | 1.07x | 0.00x | $-95.26 Million |
| 2012 | 0.00% | -7.36% | 6.21x | 0.00x | $-8.88 Million |
| 2013 | 0.00% | -69152.21% | 0.01x | 0.00x | $-154.58 Million |
| 2014 | -81.80% | -2028.05% | 0.03x | 1.17x | $-266.02 Million |
| 2015 | -74.97% | -432.56% | 0.14x | 1.23x | $-206.53 Million |
| 2016 | -54.44% | -391.94% | 0.08x | 1.83x | $-225.69 Million |
| 2017 | -247.79% | -1854.97% | 0.03x | 3.83x | $-296.92 Million |
| 2018 | 0.00% | -357.01% | 0.11x | 0.00x | $-210.37 Million |
| 2019 | 0.00% | -322.08% | 0.18x | 0.00x | $-214.07 Million |
| 2020 | 0.00% | -386.90% | 0.15x | 0.00x | $-247.64 Million |
| 2021 | 0.00% | -360.55% | 0.15x | 0.00x | $-165.57 Million |
| 2022 | 197.40% | 1698.54% | 0.08x | 1.37x | $827.95 Million |
| 2023 | -25.91% | -96.11% | 0.15x | 1.79x | $-76.49 Million |
| 2024 | -32.14% | -87.63% | 0.18x | 2.02x | $-73.97 Million |
Industry Comparison
This section compares Theravance Biopharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Theravance Biopharma Inc (TBPH) | $232.68 Million | 0.00% | 0.79x | $315.26 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |